Lung cancer ranks among the most common cancers world-wide and is the first cancer-
related cause of death. The classification of lung cancer has evolved tremendously over the …

The current landscape of targeted therapies directed against oncogenic driver alterations in
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …

Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical
problem. Although many drivers of acquired drug resistance have been identified,,–, the …

Simple Summary Lung cancer (LC) is considered one of the most common cancers globally.
Numerous studies have determined the relations between E-cigarette, or va**, products …

Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis
(BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical …

Background Resistance to osimertinib in advanced EGFR-mutated non-small cell lung
cancer (NSCLC) constitutes a significant challenge for clinicians either in terms of molecular …

The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

Introduction The emergence of osimertinib as standard of care for EGFR-mutant NSCLC has
renewed the need to understand and overcome drug resistance. We sought to understand …

Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET
amplification as a mechanism of resistance to first-line osimertinib have few treatment …

Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic
treatment options, improving patients' outcome. This benefit is not only achieved in the …